Lawrence McQuillan and Hovannes Abramyan: Tort system has consequences

Published



A diagnosis of non-Hodgkins lymphoma used to be a death sentence. Like many cancers, it was nearly untreatable, and families were forced to wait out the days until a loved one died.

But new methods of chemotherapy in addition to drugs, such as Rituxan, changed all that. One study found that a combination of the two treatments improved survival rates among patients to 70 percent, compared with 57 percent for those on chemo alone.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.